OTC Markets OTCPK - Delayed Quote USD

Jacobio Pharmaceuticals Group Co., Ltd. (JBPHF)

Compare
0.2950
0.0000
(0.00%)
At close: December 2 at 3:00:00 PM EST
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,185.0000
63,520.0000
95,746.0000
152,809.0000
486,286.0000
Cost of Revenue
22,384.0000
60,317.0000
83,112.0000
139,979.0000
44,115.0000
Gross Profit
801.0000
3,203.0000
12,634.0000
12,830.0000
442,171.0000
Operating Expense
380,338.0000
411,431.0000
486,344.0000
315,154.0000
232,781.0000
Operating Income
-379,537.0000
-408,228.0000
-473,710.0000
-302,324.0000
209,390.0000
Net Non Operating Interest Income Expense
37,314.0000
38,759.0000
22,340.0000
18,197.0000
1,647.0000
Pretax Income
-361,891.0000
-359,119.0000
-371,861.0000
-301,187.0000
-1,513,677.0000
Net Income Common Stockholders
-361,891.0000
-359,119.0000
-371,861.0000
-301,187.0000
-1,513,655.0000
Diluted NI Available to Com Stockholders
-361,891.0000
-359,119.0000
-371,861.0000
-301,187.0000
-1,513,655.0000
Basic EPS
-0.46
-0.46
-0.49
-0.40
-3.97
Diluted EPS
-0.46
-0.46
-0.49
-0.40
-3.97
Basic Average Shares
776,281.5000
772,842.0000
751,876.0000
747,293.0000
381,028.0000
Diluted Average Shares
776,281.5000
772,842.0000
751,876.0000
747,293.0000
381,028.0000
Total Operating Income as Reported
-399,205.0000
-397,878.0000
-394,201.0000
-319,384.0000
179,111.0000
Total Expenses
402,722.0000
471,748.0000
569,456.0000
455,133.0000
276,896.0000
Net Income from Continuing & Discontinued Operation
-361,891.0000
-359,119.0000
-371,861.0000
-301,187.0000
-1,513,655.0000
Normalized Income
-354,432.0000
-348,781.0000
-368,839.0000
-310,655.0000
179,310.0000
Interest Income
47,089.0000
47,071.0000
24,610.0000
18,765.0000
3,144.0000
Interest Expense
9,775.0000
8,312.0000
2,270.0000
568.0000
980.0000
Net Interest Income
37,314.0000
38,759.0000
22,340.0000
18,197.0000
1,647.0000
EBIT
-352,116.0000
-350,807.0000
-369,591.0000
-300,619.0000
-1,512,697.0000
EBITDA
-352,116.0000
-325,727.0000
-355,796.0000
-289,828.0000
-1,504,309.0000
Reconciled Cost of Revenue
22,384.0000
60,317.0000
83,112.0000
139,979.0000
44,115.0000
Reconciled Depreciation
--
25,080.0000
13,795.0000
10,791.0000
8,388.0000
Net Income from Continuing Operation Net Minority Interest
-361,891.0000
-359,119.0000
-371,861.0000
-301,187.0000
-1,513,655.0000
Total Unusual Items Excluding Goodwill
-7,459.0000
-10,338.0000
-3,022.0000
9,468.0000
-1,692,965.0000
Total Unusual Items
-7,459.0000
-10,338.0000
-3,022.0000
9,468.0000
-1,692,965.0000
Normalized EBITDA
-344,657.0000
-315,389.0000
-352,774.0000
-299,296.0000
188,656.0000
12/31/2020 - 2/28/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DRUG.CN Bright Minds Biosciences Inc.
56.00
-3.25%
 
PULM Pulmatrix, Inc.
6.01
+0.33%
 
CNTX Context Therapeutics Inc.
1.0800
-10.74%
 
TENX Tenax Therapeutics, Inc.
6.24
-2.88%
 
LYRA Lyra Therapeutics, Inc.
0.1955
-2.59%
 
BPTH Bio-Path Holdings, Inc.
0.9500
-2.92%
 
PALI Palisade Bio, Inc.
1.9100
-4.98%
 
CAPR Capricor Therapeutics, Inc.
13.19
-4.83%
 
TVGN Tevogen Bio Holdings Inc.
1.4500
+12.40%
 
CERO CERo Therapeutics Holdings, Inc.
2.9600
-20.00%